USA flag logo/image

An Official Website of the United States Government

A Novel Cassette System for the Assembly of VLP Vaccines

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43AI098253
Solicitation Year:
2012
Solicitation Topic Code:
NIAID
Solicitation Number:
PA11-096
Small Business Information
SHIFA BIOMEDICAL CORPORATION
GREAT VALLEY CORPORATE CENTER ONE GREAT VALLEY PARKWAY, SUITE 8 MALVERN, PA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: A Novel Cassette System for the Assembly of VLP Vaccines
Agency: HHS
Contract: 1R43AI098253-01A1
Award Amount: $296,731.00
 

Abstract:

DESCRIPTION (provided by applicant): Influenza and other infectious diseases are a major cause of death in the US and world-wide. Vaccination is the most cost-effective strategy to prevent these diseases. Although much progress has been made in vaccine technology, the timely design, validation and production of vaccines remains a major hurdle for the vaccine industry. The development of recombinant methods for the expression of subunit vaccines has impacted development timelines and costs but subunit vaccines frequently are not as potent as virus particles in eliciting an immune response. Virus like particles or VLPs represent one approach to bridge this potency gap but the design, expression and purification of VLPs remains problematic and the development of uniform tools to aid in vaccine production is elusive with existing technologies. In this proposal we describe a novel cassette technology of integrating recombinant proteins into the structure of VLPs. The prototype system defined in this proposal willgenerate VLPs using the influenza hemagglutinin as an immunogen. The potency of the VLP vaccine will be tested in animals in comparison to a monomeric hemagglutinin. PUBLIC HEALTH RELEVANCE: The influenza virus is highly infectious and causes bothseasonal and pandemic outbreaks. A pandemic outbreak of a highly lethal strain would cause millions of deaths worldwide. Vaccines are the most cost- effective strategy to prevent infection. New strategies are required to produce more effective vaccines and to expedite the development time for new vaccines. Our goal is to develop a novel technology for the design and development of virus like particles that can be used in vaccines.

Principal Investigator:

Michael N. Blackburn
610-400-1243
michael@shifabiomedical.com

Business Contact:

Sherin S. Abdel
610-400-1243
sherin@shifabiomedical.com
Small Business Information at Submission:

SHIFA BIOMEDICAL
GREAT VALLEY CORPORATE CENTER ONE GREAT VALLEY PARKWAY, SUITE 8 MALVERN, PA -

EIN/Tax ID: 120552979
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No